 | | Vol. 23.36 – 24 October, 2022 |
| |
|
|
|
Scientists showed a prospective interventional and observational cohort study of islet-alone and islet-after-kidney transplant recipients followed for up to eight years after intraportal infusion of one or more purified human pancreatic islet products under standardized immunosuppression.
[Diabetes Care] |
|  | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| As a proof-of-concept for adoptive T cell therapy under hyperinflammatory conditions, investigators transferred syngeneic, cytotoxicity-competent T cells into mice with virally triggered active primary HLH.
[EMBO Molecular Medicine] |
|
|
|
| Researchers treated dilated cardiomyopathy (DCM) mice harboring mutated troponin TΔK210/ΔK210 with α-galactosylceramide-pulsed dendritic cells, and evaluated the efficacy of iNKT cell activation on heart failure in DCM mice.
[Circulation-Heart Failure] |
|
|
|
| The authors generated a fully murine CAR targeting CD105, a component of the TGFβ receptor expressed on the surface of certain solid tumors and acute leukemias.
[OncoImmunology] |
|
|
|
| Researchers presented the impact of the selective adenosine A2A and A2B receptor antagonist AB928/etrumadenant on CAR T cell cytokine secretion, proliferation, and cytotoxicity.
[British Journal of Cancer] |
|
|
|
| Scientists examined the combination therapy of human mesenchymal stromal cells (MSCs) and endothelial colony-forming cells (ECFCs) to reduce the early ischemic damage and enhance angiogenesis in a pre-clinical model of acute myocardial infarction.
[Stem Cell Reviews and Reports] |
|
|
|
| This open-label, single-center and single-arm pilot study investigated the safety and efficacy of autologous stem-cell transplantation in tandem with CAR30 T-cell infusion in relapsed/refractory CD30+ lymphoma.
[Experimental Hematology & Oncology] |
|
|
|
| Researchers manufactured cGMP grade virus-specific T cells (VSTs) from healthy donors, characterized the VST product and demonstrated its safety and efficacy.
[Journal of Immunological Methods] |
|
|
|
| Investigators examined repairing effects of Taurine-loading polycaprolactone (PCL) conduits cultured with human endothelial stem cells on resected sciatic nerves.
[Regenerative Therapy] |
|
|
|
|
| The authors survey the potential of tissue-engineered surrogates in promoting muscle healing, by critically analyzing data from recent preclinical models.
[Trends in Biotechnology] |
|
|
|
| Scientists discuss the necessity of finding targets for the T cell in the cancer cells to generate CAR T cells, as well as the relevance of evaluating specificity and safety of those therapies.
[Frontiers in Oncology] |
|
|
|
|
| NKGen Biotech, Inc. announced that the US FDA has granted Investigational New Drug (IND) clearance to commence a Phase I, open-label, dose-escalation study of its cryopreserved “off-the-shelf” allogeneic blood-derived NK cell therapy (SNK02).
[NKGen Biotech, Inc.] |
|
|
|
| Hans Schreiber, MD, PhD, Professor of Pathology at the University of Chicago Medicine Comprehensive Cancer Center, received the David Jonas Memorial Award in recognition for his dedication and significant contributions to the field of cellular immunotherapy.
[The University of Chicago Medical Center] |
|
|
|
|
| December 3 – 7, 2022
Washington, DC, United States |
|
|
|
|
|
| | The University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| | King’s College London – London, England, United Kingdom |
|
|
|
| | NCI – Bethesda, Maryland, United States |
|
|
|
| | Beth Israel Deaconess Medical Center – Boston, Massachusetts, United States |
|
|
|
| | Karolinska Institutet – Solna, Sweden |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
